Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q6KF10
UPID:
GDF6_HUMAN
Alternative names:
Bone morphogenetic protein 13; Growth/differentiation factor 16
Alternative UPACC:
Q6KF10; Q6PI58
Background:
Growth/differentiation factor 6 (GDF6), also known as Bone morphogenetic protein 13, plays a pivotal role in cellular differentiation and proliferation in the retina and bone formation. It is instrumental in retinal development, apoptosis regulation, and establishing dorsal-ventral positional information. GDF6 is crucial for normal skeletal formation, including limbs, skull, digits, and axial skeleton, by defining boundaries between skeletal elements.
Therapeutic significance:
GDF6's involvement in diseases such as Klippel-Feil syndrome 1, Microphthalmia, isolated, 4, Leber congenital amaurosis 17, Multiple synostoses syndrome 4, and Deafness, autosomal recessive, 118, highlights its therapeutic potential. Understanding GDF6's role could lead to innovative treatments for these genetic disorders, focusing on its regulatory mechanisms in skeletal and retinal development.